Polymorphism of LRP4 Gene (rs9667108) among Post Menopause Women with Osteoporosis
- PMID: 37551184
- PMCID: PMC10404332
- DOI: 10.18502/ijph.v52i4.12457
Polymorphism of LRP4 Gene (rs9667108) among Post Menopause Women with Osteoporosis
Abstract
Background: Many studies have been done to identify the factors that influence the development and progression of osteoporosis. One genetic factor is polymorphisms of LRP4 gene. Regarding the lack of comprehensive study on polymorphisms of LRP4 gene in the north of Iran, mainly Mazandaran Province, we decided to investigate the polymorphism of this gene in postmenopausal women with osteoporosis.
Methods: This case-control study has been conducted at GhaemShahr Valiasr Hospital on 100 female patients with osteoporosis (average age of 58.1) and 90 healthy females without osteoporosis (average age of 55.2). After sampling and extraction of genomic DNA via of the salt deposition method, the genotype and SNP (rs9667108) polymorphism of LRP4 gene were evaluated with the PCR-RFLP method. Restriction enzymes cut the PCR products. In order to identify patients, their bone mineral density was tested by the DEXA method. The results of digestion (digestion enzyme) were analyzed by MedCalc, SPSS software, Hardy-Weinberg equilibrium, and Chi2.
Results: The statistical analysis has shown the significant relationship between SNP (rs9667108) polymorphism and the risk of osteoporosis disease in patients and control groups (P<0.05). In SNP (rs9667108), the GC genotype, compared to GG, increased the risk of disease significantly (1.556 time). Similarly, CC genotype, compared to GG genotype, increased the risk of this disease by 2.091 time.
Conclusion: The existence of mutation in the LRP4 gene could increase susceptibility to osteoporosis disease. Moreover, determining this patient's genotype in SNP (rs9667108) can be used to identify individuals who are in endanger osteoporosis.
Keywords: Osteoporosis; PCR; Polymorphism genetics; Single nucleotide polymorphisms (SNPs).
Copyright © 2023 Kavoosian et al. Published by Tehran University of Medical Sciences.
Conflict of interest statement
Conflict of Interest The authors declare that there is no conflict of interests.
Figures
References
-
- Camacho PM, Petak SM, Binkley N, et al. ( 2016). American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016. Endocr Pract, 22( 9): 1111–8. - PubMed
-
- Watts NB, Adler RA, Bilezikian JP, et al. ( 2012). Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 97( 6): 1802–22. - PubMed
-
- Buckley L, Guyatt G, Fink H, et al. ( 2017) American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017; 69 ( 8): 1521– 1537. - PubMed
-
- JAMA N. ( 2001). Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. J Am Med Assoc, 85: 785–95.
LinkOut - more resources
Full Text Sources
Miscellaneous